- Founded
- 2004
- Founder
- Asher Maroof PhD
- Shareholding
- 37.8%
- Stage
- Pre-clinical
- Employees
- 7
- Raised
- £7m seed financing
Unless stated all financials at 31 March 2026.
Re-Aim is a new early-stage pre-clinical company founded by Syncona, redefining how autoimmune diseases are treated by selectively depleting the pathogenic T cell subsets that drive chronic inflammation, autoimmunity and disease progression.
Other pre-clinical portfolio companies
